ClinicalTrials.gg
CompletedNCT05024045Updated Oct 6, 2026

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

A Phase 1 interventional study of LOXO-338 and Pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone and Lymphoma, Non-Hodgkin, sponsored by Eli Lilly and Company. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.
Updated Oct 6, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company — 5 open to participants now, 9 under way, 4 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Eli Lilly and Company.

Enrollment
11th of 12
27 · median 264
Started
2021
with 4 others
Phase 1
Only one
of the 13
Registered
6th of 13
by date

Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2021, is the only one in phase 1, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,037 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

5 of the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

Read the detailed description

This study will be conducted in 2 parts. Part 1 will evaluate LOXO-338 as monotherapy. If safety and initial evidence of efficacy of LOXO-338 monotherapy are confirmed, part 2 will evaluate the combination of LOXO-338 with the highly selective, noncovalent Bruton's tyrosine kinase (BTK) inhibitor, pirtobrutinib (LOXO-305).

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, B-cell Marginal Zone
  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma
  • B-cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Lymphoma, Mantle-Cell

Keywords

  • BTKi
  • Hematologic disease
  • Small lymphocytic lymphoma
  • BCL-2 inhibitor
  • CLL
  • SLL
  • NHL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • B-cell .
  • Patients must have received prior therapy.
  • Patients must have an objective indication for therapy.
  • performance status (ECOG PS) of 0-1.
  • Anticipated of greater than or equal to (≥) 12 weeks.
  • Adequate bone marrow function.
  • Adequate hepatic function.
  • of ≥ 60 milliliters (mL)/minute.
  • Ability to swallow tablets.
  • Ability to comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation.
  • Prior treatment-related adverse events (AEs) must have recovered to grade less than or equal to (≤) 1 or pretreatment baseline, with the exception of alopecia.
  • Men with partners of or women of childbearing potential (WOCBP) must agree to use highly effective .
  • WOCBP must not be pregnant.
  • Additional Inclusion Criteria for Patients with AL Amyloidosis

    • In Part 1 Dose Expansion, patients with AL amyloidosis are eligible based on prior detection of primary systemic light-chain amyloidosis.
    • Must have of AL amyloidosis.
    • Prior local fluorescence in-situ hybridization (FISH) testing results for t(11;14) are required to be submitted prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • Prior to identification of an appropriate RP2D (Dose Expansion) of LOXO-338, a history of known, active or suspected:

    • Richter's transformation to diffuse large B-cell lymphoma (DLBCL), prolymphocyticleukemia, or Hodgkin lymphoma
    • Transformed low grade lymphoma
    • Burkitt or Burkitt-like lymphoma
    • Diffuse large B-cell lymphoma
    • AL amyloidosis
    • Multiple myeloma
    • Lymphoblastic lymphoma or leukemia
    • Posttransplant lymphoproliferative disorder
  • Known or suspected history of central nervous system (CNS) involvement.
  • History of or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T cell (CAR-T) therapy within the past 60 days and with any of the following:

    • Active (GVHD)
    • Cytopenias from incomplete blood cell count recovery post-transplant or CAR-T therapy
    • Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity Grade > 1 from CAR-T therapy
    • Ongoing therapy
  • Known (HIV) positive, regardless of cluster of differentiation 4 (CD4) count. Unknown or negative status eligible.
  • Inability to take necessary uric acid lowering agents (i.e., allopurinol, rasburicase, orfebuxostat).
  • Concurrent anticancer therapy.
  • Concurrent treatment with strong cytochrome P450 3A4 () inhibitors or inducers that can include antifungals.
  • Use of ≥ 20 milligrams (mg) prednisone once a day (QD) or equivalent dose of per day, within 7 days of start of study treatment. Patients may not be on any dose of prednisone intended for antineoplastic use.
  • Vaccination with a within 28 days prior to start of study therapy.
  • Major surgery within four weeks of planned start of study therapy Prolongation of the corrected by Fridericia's Formula for heart rate (QTcF) greater than (>) 470 milliseconds (msec).
  • cardiovascular disease.
  • Female patient who is pregnant or lactating.
  • Active second which may preclude assessment of DLT.
  • Clinically significant active malabsorption syndrome including surgical resection of small intestine or other condition likely to affect gastrointestinal (GI) absorption of the orally administered study drugs.
  • Active or C infection.
  • Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal) or other clinically significant active disease process.
  • Active uncontrolled auto-immune cytopenia.
  • Additional Exclusion Criteria for Patients with AL Amyloidosis (Part 1 Dose-Expansion)

    • Previous or current diagnosis of symptomatic MM.
    • Heart failure that, in the opinion of the Investigator, is on the basis of ischemic heart disease.
    • Supine systolic blood pressure \< 90 mmHg, or symptomatic orthostatic hypotension in the absence of volume depletion.
    • N-terminal pro hormone natriuretic peptide (NT-proBNP) > 8500 ng/L (or BNP > 700 ng/L if NT-proBNP is not available by local or central testing).
  • Additional exclusion criteria for patients enrolled to part 2: LOXO-338 and pirtobrutinib combination

    • Prior progression or intolerance to pirtobrutinib.
    • Patients requiring therapeutic anticoagulation with warfarin.
    • Known to any component or of pirtobrutinib.
    • In patients with history of myocardial infarction or congestive heart failure, documented (LVEF) by any method of ≤ 45 percent (%) in the 12 months prior to planned start of study treatment.
    • History of uncontrolled or symptomatic arrhythmias including grade ≥ 3 arrhythmia on a prior BTK inhibitor.
    • History of major bleeding on a prior BTK inhibitor.
    • Current treatment with strong permeability glycoprotein (P-gp) inhibitors.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    LOXO-338 (Monotherapy)

    LOXO-338 administered orally.

    Drug: LOXO-338

  • Experimental
    LOXO-338 + Pirtobrutinib (Combination)

    LOXO-338 administered orally in combination with pirtobrutinib

    Drug: LOXO-338 · Drug: Pirtobrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338

    Measured by the number of patients with dose-limiting toxicities (DLTs)

    Time frame: Cycle 1 (28 Days)

  2. Part 1 - To determine the effect of LOXO-338 on response rates

    Measured by the appropriate disease specified response criteria as appropriate to tumor type

    Time frame: Estimated up to 2 years

  3. Part 2 - To determine the safety and tolerability of LOXO-338 when given in combination with pirtobrutinib

    Measured by the number of patients with dose-limiting toxicities (DLTs)

    Time frame: Cycle 2 (28 Days)

Secondary outcomes

  1. Part 1 - To characterize the pharmacokinetics (PK) properties of LOXO-338: Area under the plasma concentration versus time curve (AUC)

    PK: AUC of LOXO-338

    Time frame: Predose up to 24 hours postdose

  2. Part 1 - To characterize the PK properties of LOXO-338: Maximum drug concentration (Cmax)

    PK: Cmax of LOXO-338

    Time frame: Predose up to 24 hours postdose

  3. Part 1 - To assess preliminary antitumor activity of LOXO-338 based on overall response rate (ORR)

    ORR

    Time frame: Estimated up to 2 years

  4. Part 1 - To assess preliminary antitumor activity of LOXO-338 based on progression-free survival (PFS)

    PFS

    Time frame: Estimated up to 2 years

  5. Part 1 - To assess preliminary antitumor activity of LOXO-338 based on time-to-progression (TTP)

    TTP

    Time frame: Estimated up to 2 years

  6. Part 1 - To assess preliminary antitumor activity of LOXO-338 based on duration of response (DOR)

    DOR

    Time frame: Estimated up to 2 years

  7. Part 2 - To characterize the pharmacokinetics (PK) properties of LOXO-338 in combination with pirtobrutinib: Area under the plasma concentration versus time curve (AUC)

    PK: AUC of LOXO-338 alone and in combination with pirtobrutinib

    Time frame: Predose up to 24 hours postdose

  8. Part 2 - To characterize the PK properties of LOXO-338 and in combination with pirtobrutinib: Maximum drug concentration (Cmax)

    PK: Cmax of LOXO-338 alone and in combination with pirtobrutinib

    Time frame: Predose up to 24 hours postdose

  9. Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on overall response rate (ORR)

    ORR

    Time frame: Estimated up to 2 years

  10. Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on progression-free survival (PFS)

    PFS

    Time frame: Estimated up to 2 years

  11. Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on time-to-progression (TTP)

    TTP

    Time frame: Estimated up to 2 years

  12. Part 2 - To assess preliminary antitumor activity of LOXO-338 alone and in combination with pirtobrutinib based on duration of response (DOR)

    DOR

    Time frame: Estimated up to 2 years

07

Study locations

23 sites
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • City of Hope National Medical Center
    Duarte, California 91010-0269, United States
  • University of California San Francisco, Medical Center at Paranassus
    San Francisco, California 94117, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Indiana Blood & Marrow Transplantation (IBMT)
    Indianapolis, Indiana 46237, United States
  • University of Kansas Medical Center
    Westwood, Kansas 66205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Mayo Clinic
    Rochester, Minnesota 55905-0002, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • L'Institut Universitaire du Cancer de Toulouse Oncopole
    Toulouse, Cedex 9 31100, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Cedex 69495, France
  • CHRU de Montpellier-Hopital St Eloi
    Montpellier, 34295, France
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu
    Nantes, 44093, France
  • Institut Curie
    Paris, 75248, France
  • Centre hospitalier universitaire de Haut Leveque
    Pessac, 33604, France
  • IRCCS - AOU di Bologna
    Bologna, 40138, Italy
  • Centrum Medyczne Pratia Poznan
    Skorzewo, Poznan 60 185, Poland
  • Pratia MCM Krakow
    Krakow, 30-510, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
    Warsaw, 02-781, Poland
08

References and documents

Publications

  • Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):512-519. doi: 10.1016/j.clml.2025.01.018. Epub 2025 Jan 28. PubMed 40000354 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2023, 20 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 20 months is below that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Mar 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 27, 2021
StartActual
Sep 30, 2021
Primary completionActual
Jun 14, 2023
CompletionActual
Mar 2, 2026was Apr 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Apr 1, 2026→Mar 2, 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Study completion Apr 1, 2026→Mar 2, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05024045
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Sep 30, 2021
Primary completion
Jun 14, 2023
Completion
Mar 2, 2026
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bcl-2 Inhibitor LOXO-338

Start the discussion